Pollens - grasses, fescue, meadow festuca elatior - Biologic Drug Details

Summary for pollens - grasses, fescue, meadow festuca elatior

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, fescue, meadow festuca elatior

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, fescue, meadow festuca elatior Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, fescue, meadow festuca elatior Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, fescue, meadow festuca elatior Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pollen-Based Biologic Drugs: Grasses, Fescue, Meadow Festuca Elatior

Last updated: February 20, 2026

What are the current market drivers influencing pollen-based biologic drugs?

The biologic drugs derived from pollen, notably grasses, fescue, and meadow Festuca elatior, are primarily developed for allergy immunotherapy. The growing prevalence of allergic rhinitis and related respiratory conditions, especially in urbanized regions, fuels demand. Global allergy prevalence is projected to reach 30-40% by 2050, according to the World Allergy Organization (WAO). Increased awareness about immunotherapy benefits and regulatory support for allergen-specific treatments drive market growth.

Major drivers include:

• Rising allergy and asthma incidence
• Enhanced awareness of allergy treatment options
• Advances in allergen standardization and delivery methods
• Expanding commercialization through biosimilar and generic allergen extracts

How does the supply chain impact the production of pollen-based biologics?

The production process involves harvesting pollen from specific grasses, fescue, and meadow Festuca elatior, followed by extraction, purification, and formulation. Limitations in sustainable pollen sourcing, seasonal variability, and environmental concerns affect output stability and costs.

Key supply chain factors:

• Seasonal harvesting restricts availability to specific periods
• Weather conditions influence pollen yield quality and quantity
• Standardization challenges affect batch consistency
• Cultivation practices influence allergen potency

What are the regulatory considerations affecting market development?

Regulatory pathways vary by region, influencing the innovation timeline and commercialization. The U.S. Food and Drug Administration (FDA) classifies pollen-based immunotherapeutics as biologics, requiring an Investigational New Drug (IND) application and Biologics License Application (BLA). European Medicines Agency (EMA) follows similar procedures.

Regulation impacts:

• Approval timelines ranging from 5 to 8 years
• Cost of clinical trials, estimated between $200-400 million
• Focus on demonstrating safety, efficacy, and standardized manufacturing

What is the current financial outlook for pollen-derived biologic therapeutics?

The allergy immunotherapy market was valued at approximately $6 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 8% through 2030. The segment involving pollen-specific products constitutes about 65% of the total allergy immunotherapy market.

Revenue projections:

Year	Market Value (USD billions)	CAGR	Notes
2023	6.48	8%	Continued growth driven by new products
2025	7.87		Inclusion of higher-potency extracts
2030	11.50		Market expansion and regulatory approvals

Major players such as ALK-Abelló, Stallergenes Greer, and Allergy Therapeutics dominate the market through proprietary pollen extracts.

R&D investments focus on:

• Novel delivery systems
• Personalized allergen immunotherapy
• Biotechnology approaches to enhance efficacy and safety

How do competitive and technological trends shape future market trajectories?

Technological innovation is moving toward recombinant allergen production, allowing for precise allergen profiles and reduced standardization variability. Companies invest in nanotechnology for sustained-release formulations and mobile applications for patient compliance management.

Competitive landscape involves:

• Mergers and acquisitions to expand product portfolios
• Strategic alliances with biotech firms
• Development of biosimilar products to lower prices and increase accessibility

What are the key risks and barriers impacting market growth?

Risks include:

• Regulatory delays or rejections due to safety concerns
• Variability in pollen allergenicity based on environmental factors
• Limited patient acceptance of allergen immunotherapy, often requiring multiple clinic visits
• Competition from biologics targeting other pathways, such as monoclonal antibodies

Barriers:

• High costs associated with clinical trials
• Complex manufacturing processes
• Need for precise standardization and quality control

What is the outlook for investment and R&D in pollen-derived biologics?

Investment is centered on:

• Genetically engineered pollen allergens
• Novel delivery mechanisms, including sublingual tablets and injectable forms
• Personalized allergen extracts based on patient-specific sensitivities

R&D focus aims to reduce treatment duration, improve safety profile, and expand indications beyond allergies, such as autoimmune diseases.

Key Takeaways

• The allergy immunotherapy market is expanding, driven by rising allergy prevalence and innovations in allergen standardization.
• Pollen-based biologics face supply chain and regulation challenges that influence cost and time-to-market.
• Financial growth is sustainable, with projected market size reaching $11.5 billion by 2030.
• Technological advances, such as recombinant allergen development, shape future market dynamics.
• High R&D costs and regulatory hurdles remain barriers to rapid commercialization.

FAQs

1. How does environmental change affect pollen allergen variability?
Environmental factors like climate change and pollution alter pollen production and allergen potency, potentially impacting efficacy and standardization in biologic formulations.

2. Are pollen-based biologics safe compared to traditional allergy medications?
They are generally safe within controlled clinical settings. Adverse effects are rare but can include local reactions; rigorous safety trials underpin regulatory approval.

3. What role do biosimilars play in this market?
Biosimilars aim to lower costs and increase access, especially in markets where original biologics are priced high. Their approval depends on demonstrating similarity to reference products.

4. How does patient compliance influence market growth?
Improved formulations that shorten treatment duration and develop user-friendly delivery systems can enhance compliance, supporting market expansion.

5. What are the main technological trends in allergen production?
Recombinant DNA technology and nanotechnology provide pathways toward standardized, safer, and more effective allergen formulations.

---

References

[1] World Allergy Organization. (2020). Global allergy prevalence forecast.
[2] MarketsandMarkets. (2023). Allergy Immunotherapy Market by Product, Route of Administration, and Region.
[3] U.S. Food and Drug Administration. (2022). Biologics regulatory guidelines.
[4] European Medicines Agency. (2022). Guidance on allergen immunotherapy development.